Compare RR & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RR | DTIL |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 614.9M | 214.7M |
| IPO Year | 2023 | 2019 |
| Metric | RR | DTIL |
|---|---|---|
| Price | $1.67 | $7.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $4.00 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 6.1M | 243.3K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,045,000.00 | ★ $1,070,000,000.00 |
| Revenue This Year | $75.68 | N/A |
| Revenue Next Year | $78.28 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.99 | N/A |
| 52 Week Low | $1.30 | $3.53 |
| 52 Week High | $7.43 | $9.62 |
| Indicator | RR | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 46.86 | 40.71 |
| Support Level | $1.54 | $7.18 |
| Resistance Level | $1.83 | $7.92 |
| Average True Range (ATR) | 0.13 | 0.40 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 30.68 | 5.61 |
Richtech Robotics Inc is a robotics and artificial intelligence (AI) technology company focused on developing embodied AI systems that aims to improve the efficiency and productivity of businesses. The company trains proprietary artificial intelligence models on in-house data to operate robotic systems in the real world. It designs, engineers, manufactures, and deploys next generation embodied AI systems to serve a wide range of industries, including food service, retail, industrial manufacturing, automotive, healthcare, and hospitality. The company's offerings include Commercial Robotic Products, Industrial Robotic Products and Data Services. The company generated the majority of its revenue through product revenue (i.e. outright hardware sales).
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).